Cord Blood News Volume 4.14 | Apr 12 2012

Reduced Intensity Conditioning Transplantation in Acute Leukemia: The Effect of Source of Unrelated Donor Stem Cells on Outcomes
Investigators report the relative efficacy of co-infusing two umbilical cord blood units compared to peripheral blood progenitor cells from 8/8 or 7/8 HLA matched unrelated donors. [Blood] Abstract

TET2 Is Essential for Survival and Hematopoietic Stem Cell Homeostasis
Researchers’ data indicates that ten-eleven-translocation 2 (TET2) plays a critical role in survival and hematopoietic stem cell homeostasis. [Leukemia] Abstract

Human Insulin Secreted from Insulinogenic Xenograft Restores Normoglycemia in Type I Diabetic Mice without Immunosuppression
Researchers examined therapeutic potential of human amnion-derived insulin-secreting cells for type 1 diabetes. Human amniotic mesenchymal stem cells were isolated from amnion, and cultivated to differentiate into insulin-secreting cells in vitro. [Cell Transplant] Abstract

RNA Sensors Enable Human Mast Cell Anti-Viral Chemokine Production and Interferon-Mediated Protection in Response to Antibody-Enhanced Dengue Virus Infection
In order to obtain a global view of dengue virus-induced gene regulation in mast cells, primary human cord blood-derived mast cells and the KU812 and HMC-1 mast cell lines were infected with dengue virus in the presence of dengue-immune sera and their responses were evaluated at the mRNA and protein levels. [PLoS One] Abstract

Twice Daily i.v. Bolus Tacrolimus Infusion for GvHD Prophylaxis in Children Undergoing Stem Cell Transplantation
Researchers investigated the safety and efficacy of twice daily bolus infusions of i.v. tacrolimus in 33 children undergoing hematopoietic stem cell transplantation. [Bone Marrow Transplant] Abstract

Human Monocyte Responsiveness to the Commensal Bacterium Staphylococcus epidermidis Develops Late in Gestation
Cord and peripheral blood mononuclear cells were stimulated with Staphylococcus epidermidis and a range of innate immune responses assessed, including phagocytosis, intracellular killing, Toll-like receptor (TLR) pathway transcriptional activation, cytokine production, TLR2 and TLR4 expression and cell signaling. [Pediatr Res] Abstract

Comparison of Immunomodulatory Effects of Placenta Mesenchymal Stem Cells with Bone Marrow and Adipose Mesenchymal Stem Cells
Researchers examined and compared immunomodulatory function of chorionic plate-derived mesenchymal stem cells (MSCs) with that of bone marrow-derived MSCs and adipose-derived MSCs using co-culture system with activated T-cells derived from human umbilical cord blood exposed to anti-CD3 and anti-CD28 which are T-cell activating monoclonal antibodies. [Int Immunopharmacol] Abstract

Cord Blood Interleukin-6 Predicts Neonatal Morbidities In Pcr Positive Ureaplasma urealyticum Preterm Infants
Researchers’ objectives were to evaluate the clinical significance of Ureaplasma urealyticum recovery from umbilical cord blood, using PCR, and its association to umbilical cord interleukin-6 levels and neonatal morbidity in preterm infants. [J Matern Fetal Neonatal Med] Abstract

China Cord Blood Corporation Announces Investment by KKR
China Cord Blood Corporation (CCBC) and Kohlberg Kravis Roberts & Co. L.P. (KKR) announced that they have entered into agreements under which KKR China Growth Fund L.P. is expected to invest $65 million into CCBC to support its further business expansion and to capitalize on China’s fast growing healthcare services industry. [China Cord Blood Corporation] Press Release

ThermoGenesis Announces Registration Approval for BioArchive in China
ThermoGenesis Corp. announced that China’s State Food and Drug Administration has approved the registration of the BioArchive^® System (BioArchive), enabling its direct commercial sale by the Company into the People’s Republic of China. [ThermoGenesis Corp.] Press Release

NIH Names Dr. Gary H. Gibbons Director of the National Heart, Lung, and Blood Institute
National Institutes of Health (NIH) Director Francis S. Collins announced the selection of Gary H. Gibbons, as the new director of the NIH’s National Heart, Lung, and Blood Institute. [National Institutes of Health, United States] Press Release

Athersys Receives U.S. Patent Covering the Suppression of Graft-versus-Host Disease Associated with Hematopoietic Stem Cell Transplantation with Adult Stem Cells
Athersys, Inc. announced that it has been granted U.S. patent 8,147,824 that covers the use of non-embryonic, multipotent stem cells for the reduction in severity or prevention of Graft-versus-Host Disease. [Athersys, Inc.] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Hematology (STEMCELL Technologies, Inc.)

Scientist – hPSC (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

Stem Cell Technician (Kelly Scientific Resources)

Medical Technologist II – Cellular Therapy (San Diego Blood Bank)


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.